


Application Number	10/502,001
Filing Date	July 19, 2004
First Named Inventor	Malek, Nisar P.
Art Unit	1632
Examiner Name	Unassigned
Attorney Docket Number	14538A-006610US

Remarks	The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.
---------	--

Reg. No.	32,928
----------	--------

Date Aug. 24, 2008

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on Aug. 24, 2005



By: JM Shollen

PATENT
Attorney Docket No.: 14538A-006610US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Nisar P. Malek *et al.*

Application No.: 10/502,001

Filed: July 19, 2004

For: COMPOSITIONS AND METHODS
FOR INCREASING ANIMAL SIZE
AND GROWTH RATE

Customer No.: 20350

Confirmation No.: 6809

Examiner: Unassigned

Art Unit: 1632

**INFORMATION DISCLOSURE
STATEMENT UNDER
37 CFR §1.97 and §1.98**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached forms PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the non-patent references, Cite Nos. AC - BR, are enclosed in compliance with the requirements of 1287 OG 163.

Also enclosed is a copy of the International Search Report corresponding to the PCT application.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicant believes that no fee is required for submission of this statement. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Date: 24 August 2005

By: Brian W. Poor
Brian W. Poor
Reg. No. 32,928

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 206-467-9600
Fax: 415-576-0300
BWP:mmm
60542380 v1



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/502,001
		Filing Date	July 19, 2004
		First Named Inventor	Malek, Nisar P.
		Art Unit	1632
Examiner Name	Unassigned		
Sheet 1	of 4	Attorney Docket Number	14538A-006610US


U.S. PATENT DOCUMENTS+					
Examiner Initials*	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-5,958,769	09-28-1999	Roberts <i>et al.</i>	
	AB	US-6,242,575	06-05-2001	Massague <i>et al.</i>	

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>
								<input type="checkbox"/>

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60542380 v1




Substitute for form PTO/SB/08B INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/502,001	
			Filing Date	July 19, 2004	
			First Named Inventor	Malek, Nisar P.	
			Art Unit	1632	
			Examiner Name	Unassigned	
Sheet	2	of	4	Attorney Docket Number	14538A-006610US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AC	AGRAWAL, D. <i>et al.</i> , "Repression of p27 ^{Kip1} synthesis by platelet-derived growth factor in BALB/c 3T3 cells," <i>Mol. Cell. Biol.</i> , 16(8):4327-4336 (Aug. 1996).	
	AD	BAI, C. <i>et al.</i> , "SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box," <i>Cell</i> , 86(2):263-274 (Jul. 26, 1996).	
	AE	CARRANO, A. <i>et al.</i> , "SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27," <i>Nat. Cell. Biol.</i> , 1(4):193-199 (Aug. 1999).	
	AF	FELDMAN, R.M. <i>et al.</i> , "A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p," <i>Cell</i> , 91(2):221-230 (Oct. 17, 1997).	
	AG	FERO, M. <i>et al.</i> , "A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27 ^{Kip1} -deficient mice," <i>Cell</i> , 85(5):733-744 (May 31, 1996).	
	AH	FRIEDRICH, G. and SORIANO, P., "Promoter traps in embryonic stem cells: a genetic screen to identify and mutate developmental genes in mice," <i>Genes Dev.</i> , 5(9):1513-1523 (Sept. 1991).	
	AI	GOULD, K. <i>et al.</i> , "Phosphorylation at Thr167 is required for <i>Schizosaccharomyces pombe</i> p34 ^{cdc2} function," <i>EMBO J.</i> , 10(11):3297-3309 (Nov. 1991).	
	AJ	HANNON, G. and BEACH, D., "p15 ^{INK4B} is a potential effector of TGF- β -induced cell cycle arrest," <i>Nature</i> , 371(6494):257-261 (Sept. 15, 1994).	
	AK	HATAKEYAMA, M. <i>et al.</i> , "The cancer cell and the cell cycle clock," <i>Cold Spring Harb. Symp. Quant. Biol.</i> , 59:1-10 (1994).	
	AL	HENGST, L. and REED, S., "Translational control of p27 ^{Kip1} accumulation during the cell cycle," <i>Science</i> , 271(5257):1861-1864 (Mar. 29, 1996).	
	AM	HOLMES, J. and SOLOMON, M., "A predictive scale for evaluating cyclin-dependent kinase substrates. A comparison of p34 ^{cdc2} and p33 ^{cdk2} ," <i>J. Biol. Chem.</i> , 271(41):25240-25246 (Oct. 11, 1996).	
	AN	JEFFREY, P. <i>et al.</i> , "Mechanism of CDK activation revealed by the structure of a cyclinA-CDK2 complex," <i>Nature</i> , 376(6538):313-320 (Jul. 27, 1995).	
	AO	KATO, J. <i>et al.</i> , "Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27 ^{Kip1}) of cyclin-dependent kinase 4 activation," <i>Cell</i> , 79(3):487-496 (Nov. 4, 1994).	
	AP	KOFF, A. <i>et al.</i> , "Negative regulation of G1 in mammalian cells: inhibition of cyclin E-dependent kinase by TGF- β ," <i>Science</i> , 260(5107):536-539 (Apr. 23, 1993).	
	AQ	LEE, MH <i>et al.</i> , "Cloning of p57 ^{KIP2} , a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution," <i>Genes Dev.</i> , 9(6):639-649 (Mar. 15, 1995).	
Examiner Signature		Date Considered	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.




Substitute for form PTO/SB/08B INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/502,001	
			Filing Date	July 19, 2004	
			First Named Inventor	Malek, Nisar P.	
			Art Unit	1632	
			Examiner Name	Unassigned	
Sheet	3	of	4	Attorney Docket Number	14538A-006610US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AR	LEONE, G. <i>et al.</i> , "Myc and Ras collaborate in inducing accumulation of active cyclin E/Cdk2 and E2F," <i>Nature</i> , 387(6631):422-426 (May 22, 1997).	
	AS	MALEK, N. <i>et al.</i> , "A mouse knock-in model exposes sequential proteolytic pathways that regulate p27 ^{Kip1} in G1 and S phase," <i>Nature</i> , 413(6853):323-327 (Sept. 20, 2001).	
	AT	MILLARD, S.S. <i>et al.</i> , "A U-rich element in the 5' untranslated region is necessary for the translation of p27 mRNA," <i>Mol. Cell. Biol.</i> , 20(16):5947-5959 (Aug. 2000).	
	AU	MILLARD, S.S. <i>et al.</i> , "Enhanced ribosomal association of p27 ^{Kip1} mRNA is a mechanism contributing to accumulation during growth arrest," <i>J. Biol. Chem.</i> , 272(11):7093-7098 (Mar. 14, 1997).	
	AV	MONTAGNOLI, A. <i>et al.</i> , "Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation," <i>Genes Dev.</i> , 13(9):1181-1189 (May 1, 1999).	
	AW	MORGAN, D., "Principles of CDK regulation," <i>Nature</i> , 374(6518):131-134 (Mar. 9, 1995).	
	AX	MORIMOTO, M. <i>et al.</i> , "Modification of cullin-1 by ubiquitin-like protein Nedd8 enhances the activity of SCF ^{Skp2} toward p27 ^{Kip1} ," <i>Biochem. Biophys. Res. Commun.</i> , 270(3):1093-1096 (Apr. 21, 2000).	
	AY	MÜLLER, D. <i>et al.</i> , "Cdk2-dependent phosphorylation of p27 facilitates its Myc-induced release from cyclin E/cdk2 complexes," <i>Oncogene</i> , 15(21):2561-2576 (Nov. 20, 1997).	
	AZ	NAGY, A. <i>et al.</i> , "Dissecting the role of N-myc in development using a single targeting vector to generate a series of alleles," <i>Curr. Biol.</i> , 8(11):661-664 (May 21, 1998).	
	BA	NOURSE, J. <i>et al.</i> , "Interleukin-2-mediated elimination of the p27 ^{Kip1} cyclin-dependent kinase inhibitor prevented by rapamycin," <i>Nature</i> , 372(6506):570-573 (Dec. 8, 1994).	
	BB	O'HAGAN, R. <i>et al.</i> , "Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression," <i>Genes Dev.</i> , 14(17):2185-2191 (Sept. 1, 2000).	
	BC	PARDEE, A., "A restriction point for control of normal animal cell proliferation," <i>Proc. Natl. Acad. Sci. USA.</i> , 71(4):1286-1290 (Apr. 1974).	
	BD	POLYAK, K. <i>et al.</i> , "Cloning of p27 ^{Kip1} , a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals," <i>Cell</i> , 78(1):59-66 (Jul. 15, 1994).	
	BE	ROLFE, M. <i>et al.</i> , "The ubiquitin-mediated proteolytic pathway as a therapeutic area," <i>J. Mol. Med.</i> , 75(1):5-17 (Jan. 1997).	
	BF	SERRANO, M. <i>et al.</i> , "A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4," <i>Nature</i> , 366(6456):704-707 (Dec. 16, 1993).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/502,001	
			Filing Date	July 19, 2004	
			First Named Inventor	Malek, Nisar P.	
			Art Unit	1632	
			Examiner Name	Unassigned	
Sheet	4	of	4	Attorney Docket Number	14538A-006610US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BG	SHEAFF, R. et al., "Cyclin E-CDK2 is a regulator of p27 ^{Kip1} ," <i>Genes Dev.</i> , 11(11):1464-1478 (Jun. 1, 1997).	
	BH	SHERR, C. and ROBERTS, J. "CDK inhibitors: positive and negative regulators of G ₁ -phase progression," <i>Genes Dev.</i> , 13(12):1501-1512 (Jun. 15, 1999).	
	BI	SHILO, B.Z. and WEINBERG, R., "DNA sequences homologous to vertebrate oncogenes are conserved in <i>Drosophila melanogaster</i> ," <i>Proc. Natl. Acad. Sci. USA.</i> , 78(11):6789-6792 (Nov. 1981).	
	BJ	SKOWYRA, D. et al., "F-box proteins are receptors that recruit phosphorylated substrates to the SCF ubiquitin-ligase complex," <i>Cell</i> , 91(2):209-219 (Oct. 17, 1997).	
	BK	SOLOMON, M. et al., "CAK, the p34 ^{cdc2} activating kinase, contains a protein identical or closely related to p40 ^{MO15} ," <i>EMBO J.</i> , 12(8):3133-3142 (Aug. 1993).	
	BL	SOLOMON, M. et al., "Role of phosphorylation in p34 ^{cdc2} activation: Identification of an activating kinase," <i>Mol. Biol. Cell</i> , 3(1):13-27 (Jan. 1992).	
	BM	SUTTERLÜTY, H. et al., "p45 ^{SKP2} promotes p27 ^{Kip1} degradation and induces S phase in quiescent cells," <i>Nat. Cell Biol.</i> , 1(4):207-214 (Aug. 1999).	
	BN	TORCHINSKY, C. et al., "Regulation of p27 ^{Kip1} during gentamicin mediated hair cell death," <i>J. Neurocytol.</i> , 28:913-924 (Oct.-Nov. 1999).	
	BO	TOYOSHIMA, H. and HUNTER, T., "p27, a novel inhibitor of G ₁ cyclin-Cdk protein kinase activity, is related to p21," <i>Cell</i> , 78(1):67-74 (Jul. 15, 1994).	
	BP	TSVETKOV, L. et al., "p27 ^{Kip1} ubiquitination and degradation is regulated by the SCF ^{Skp2} complex through phosphorylated Thr187 in p27," <i>Curr. Biol.</i> , 9(12):661-664 (Jun. 7, 1999).	
	BQ	VLACH, J. et al., "Growth arrest by the cyclin-dependent kinase inhibitor p27 ^{Kip1} is abrogated by c-Myc," <i>EMBO J.</i> , 15(23):6595-6604 (Dec. 2, 1996).	
	BR	XIONG, Y. et al., "p21 is a universal inhibitor of cyclin kinases," <i>Nature</i> , 366(6456):701-704 (Dec. 16, 1993).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.